Andrx/Millennium/Enzon/Sepracor - 500 Beiträge pro Seite

[Nummer2]

Hi!

Mal wieder ein neuer Thread zu meinen Lieblingen. Hier sollen Infos, Gerüchte, News, Einschätzungen behandelt werden.
Ich eröffne mal mit einer Doppelfrage: Wer weiß was über die Kursverluste am 25.10. bei Andrx und Millennium?
Millennium ist wohl technisch bedingt (wieder mal am ATH abgeprallt). Aber was ist bei ADRX los?? News? Der Kurs läuft ja in letzter Zeit extrem zickzack, und ich dachte ADRX wäre eher konservativ. Doch wohl keine Trader?

Danke für alle Infos!
Bye, Nummer2

[Nummer2]

OK, dann antworte ich mir eben selber.
Andrx hat gestern seine Q3-Zahlen bekanntgegeben. Lagen 2 Cents über den Analystenschätzungen (0.26 statt 0.24 $). Aussichten für die nächsten Quartale werden als sehr gut bezeichnet. Umsätze der 2 Hauptprodukte sollen weiter steigen.
Klingt gut, aber wohl nicht gut genug, um wieder ans ATH anzuschließen.

Bye, Nummer2

[Börsenguru2001]

Wann kommen die Quartalszahlen von MLNM und Sepracor??????????

[Industriegigant]

Millennium kamen schon, waren O.K.

Millennium bei Islandbook.com schon auf 78$, die explodieren gerade.

DER INDUSTRIEGIGANT

[Nummer2]

Waren schon:

SEPRACOR 24.10.00

Sepracor Announces Third Quarter 2000 Financial Results


MARLBOROUGH, Mass., Oct. 24 /PRNewswire/ -- Sepracor Inc. (Nasdaq: SEPR) today announced its consolidated financial results for the third quarter of 2000. For the three months ended September 30, 2000, Sepracor`s consolidated revenues from continuing operations were $11.5 million, of which revenues from pharmaceutical product sales were approximately $9.6 million. The net loss was $45.2 million, or $0.62 per share. These consolidated results compare with consolidated revenues from continuing operations of $2.5 million, of which revenues from pharmaceutical product sales were approximately $1.8 million, and a net loss of $55.7 million, or $0.84 per share, for the three months ended September 30, 1999.

For the nine months ended September 30, 2000, Sepracor`s consolidated revenues from continuing operations were $60.9 million, of which revenues from pharmaceutical product sales were $32.6 million, and the net loss was $130.6 million, or $1.80 per share. This compares with consolidated revenues from continuing operations of $10.2 million, and a net loss of $122.7 million, or $1.87 per share, for the nine months ended September 30, 1999.

As of September 30, 2000, Sepracor had approximately $680 million in consolidated cash, cash equivalents and marketable securities.

During the third quarter, Sepracor announced that it has begun Phase III studies for (S)-zopiclone for the treatment of insomnia. A second Phase III clinical study, which began in October, will run in parallel. (S)-Zopiclone is a single-isomer version of racemic zopiclone, a non-benzodiazepine, rapid-acting hypnotic marketed by Aventis Pharma AG under the brand names of IMOVANE(R) and AMOBAN(R). It is available in approximately 80 countries worldwide but has never been submitted for approval in the U.S.

Also during the quarter, the Company announced that it has successfully completed a 400-patient clinical efficacy trial for (S)-zopiclone for the treatment of transient insomnia. Patients treated with (S)-zopiclone successfully achieved all efficacy endpoints, including rapid onset of action and long duration of activity, resulting in patients falling asleep and staying asleep through the night. All endpoints were clinically relevant and statistically significant (p<0.05). Additionally, (S)-zopiclone was well tolerated in this study.

According to the National Sleep Foundation, sleep disorders affect approximately 84 million people in the United States. The U.S. market for prescription sleep products is approaching $1 billion and growing at a rate of 20 percent per year. Insomnia may be caused by a number of factors including stress, anxiety, environmental temperatures, change in the surrounding environment, sleep/wake schedule problems such as those due to jet lag, and medication side effects.

In addition, Sepracor has begun a large-scale Phase II study of (R)-didesmethylsibutramine ((R)-DDMS) for the treatment of depression. (R)-DDMS is a potent serotonin, norepinephrine and dopamine reuptake inhibitor. This unique triple mechanism of action may offer improvements in the treatment of disorders such as depression and attention deficit hyperactivity disorder (ADHD). The company believes that there is no single product with this triple mechanism of action approved for depression or ADHD. Physicians often prescribe various combinations of drugs to achieve a similar outcome, which demonstrates that this multiple effect has the potential for therapeutic synergy.

Also during the quarter, Aventis Pharma Ltd. acquired an approval from the Ministry of Health and Welfare in Japan for the anti-allergic agent, fexofenadine, which is marketed in the U.S. by Aventis as ALLEGRA(R) brand fexofenadine hydrochloride. The product will be manufactured and distributed by Aventis Pharma Ltd. upon expected National Health Insurance (NHI) drug price listing. Sepracor expects to receive royalties on product sales.

Additionally, Schering-Plough Corporation recently announced that the Committee on Proprietary Medicinal Products (CPMP) of the European Agency for the Evaluation of Medicinal Products (EMEA) has issued a positive opinion recommending approval of the nonsedating antihistamine, desloratadine 5 mg, as a once-daily treatment for seasonal allergic rhinitis (SAR). Upon final approval, desloratadine will be marketed within the European community primarily under the brand name AERIUS(TM). Upon issuance of patents that are pending in the European Patent Office, Sepracor will receive royalties on sales.

Sepracor has a total of nine compounds in human clinical trials. XOPENEX(R) (levalbuterol HCl) inhalation solution is in post-market clinical studies. XOPENEX is indicated for the treatment and prevention of bronchospasm in patients 12 years of age and older with reversible obstructive airway disease, such as asthma. The Company is preparing a New Drug Application (NDA) for norastemizole, its nonsedating antihistamine, which is scheduled for filing with the U.S. Food and Drug Administration in the first quarter of 2001. (S)-Zopiclone is in Phase III studies for the treatment of insomnia. Scheduled to advance into Phase III studies in 2001 are (S)-oxybutynin for the treatment of urge urinary incontinence, (R,R)-formoterol, a long-acting bronchodilator, and (R)-DDMS for depression. (R)-DDMS for ADHD, (S)-DDMS for sexual dysfunction, and (S)-doxazosin for benign prostatic hyperplasia are currently in Phase I. Additionally, the Company plans to file Investigational New Drug applications for new clinical candidates next year.

Sepracor also recently announced that Eli Lilly and Company has terminated its exclusive license agreement regarding (R)-fluoxetine. Based on a review of the available clinical data, (R)-fluoxetine, at the highest dose tested, demonstrated a small but statistically significant increase in QTc prolongation. The timetable for development of (R)-fluoxetine would delay NDA submission by at least two years. Given the extended development timetable and an assessment of the competitive environment, which includes Sepracor`s Phase II compound for depression, (R)-DDMS, Sepracor has elected not to pursue the (R)-fluoxetine program at this time.





MILLENNIUM 17.10.00

Millennium Reports Third Quarter 2000 Financial Results

-- Exercise of Over-Allotment from Equity Offering Brings Cash Balance to Over
$1.4 Billion --


CAMBRIDGE, Mass., Oct. 17 /PRNewswire/ -- Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM) today reported consolidated financial results for the three and nine months ended September 30, 2000. (Photo: http://www.newscom.com/cgi-bin/prnh/19991220/MLNMLOGO )

Revenue for the quarter ended September 30, 2000 was $49.8 million compared to $40.3 million for the same period in 1999. This is the first quarter that the company recognized revenue from its ground-breaking alliance with Aventis Pharma. Millennium`s corporate alliances provide the Company with substantial revenues, enabling technologies and rights that allow the Company to build upon its proprietary drug discovery and development product pipeline and technology base.

Expenditures for research and development for the quarter ended September 30, 2000 were $68.8 million versus $38.4 million for the same period in 1999. The increase is primarily due to Millennium`s investments in all aspects of research and development necessary to execute its strategy of becoming a major biopharmaceutical company. These include investments in its science and technology platform, as well as investments in development candidates and the preclinical pipeline, which were not in place in the prior period.

General and administrative expenses for the quarter ended September 30, 2000 were $12.4 million versus $8.3 million for the same period in 1999. This increase is due to the expansion of operations and infrastructure necessary to support growth at all levels of Millennium`s business.

Net operating loss, before amortization charges and debt conversion expenses, for the quarter ended September 30, 2000 was $25.9 million or $0.13 per basic and diluted share, compared to net operating loss, before amortization charges and debt conversion expenses, of $3.8 million or $0.03 per basic and diluted share for the same period in 1999. In addition, Millennium recorded amortization charges of $14.5 million for the quarter resulting from strategic acquisitions. During the quarter, Millennium paid an aggregate of $49.3 million in cash to the holders of Millennium`s convertible notes in order to induce the conversion of their notes into Millennium common stock. These conversions resulted in the retirement of $275.1 million of outstanding principal of Millennium convertible notes, and the issuance of approximately 6.5 million shares of Millennium common stock.

As of September 30, 2000, Millennium had approximately $679 million in cash, cash equivalents and marketable securities. In October, the Company raised an additional $767 million in a public offering of its common stock (including the underwriters` exercise of their over-allotment option), bringing the total cash balance as of October 17, 2000 to over $1.4 billion.

"We are on track to achieve our corporate goals for 2000, including developing the industry`s broadest emerging clinical and preclinical pipeline, enhancing productivity by addressing key bottlenecks in the drug discovery and development process, and building a world class senior leadership team," said Mark Levin, chief executive officer of Millennium. "With over $1.4 billion in cash, Millennium has the resources to continue to invest in our pipeline and to enhance our downstream capabilities, moving us closer to our goal of building the biopharmaceutical company of the future."


Quelle: www.nasdaq.com/PR newswire

[Börsenguru2001]

Danke für die Infos!
Da war ich gerade im Urlaub!

[chewie_a]

Ich finde die zahlen von Andrx eher als schlecht. Klar sie haben die Analystenschätzungen übertroffen was den gewinn betrifft, aber vom Umsatz her bin ich stark enttäuscht und scheinbar auch die Amis, daher wohl der Kurseinbruch. letztes Jahr sahen wie dort fast 100% und dieses Jahr gerade mal ca. 5% zum Vorjahreszeitraum, wo ist da jetzt die Zukunftsperspektive ? Ich habe sie jetzt eng mit Stops abgesichert !

Good trade